Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Researchers in the United States have conducted a study showing that activation of the complement system is specifically implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback